. 2013 Jan 23;6:1–14. doi: 10.2147/IDR.S26134

Table 3.

Randomized controlled trials evaluating oral steroids in CRSwNP

Author	Year	N	Outcome measures	Treatment groups	Results
Hissaria et al⁸⁰	2006	41	Symptoms, MRI, endoscopy	Prednisolone 50 mg daily versus placebo × 14 days	Improved symptoms, MRI and endoscopic appearance in steroid group versus control
Kroflic et al⁸¹	2006	40	Symptoms, endoscopy, histology, intraoperative bleeding	Methylprednisolone 1 mg/kg daily versus nasal furosemide × 7 days pre-ESS	Improved symptoms and polyp size in both groups with no clinical difference between groups
van Zele et al⁸²	2010	47	Endoscopy, rhinometry, symptoms, SEC, nasal IL-5, IgE, MMP-9, ECP	Methylprednisolone taper over 20 days versus oral doxycycline × 20 days versus placebo	Improved polyp size, nasal patency, inflammatory markers and symptoms in steroid group versus placebo
Kirtsreesakul et al⁸³	2011	109	Symptoms,rhinometry,endoscopy	Prednisolone 50 mg daily versus placebo × 14 days	Improved symptoms, nasal patency and polyp size in steroid group versus control
vaidyanathan et al⁸⁴	2011	60	Endoscopy, symptoms, QoL, rhinometry, CRP, EDN	Prednisolone 25 mg daily versus placebo × 14 days, both followed by intranasal fluticasone	Improved polyp size, symptoms, QoL, serum EDN, and CRP in steroid group versus control

Abbreviations: CRSwNP, chronic rhinosinusitis with nasal polyposis; MRI, magnetic resonance imaging; ESS, endoscopic sinus surgery; SEC, serum eosinophil count; IL-5, interleukin 5; IgE, immunoglobulin E; MMP-9, matrix metalloproteinase-9; ECP, eosinophilic cationic protein; QoL, quality of life; CRP, C-reactive protein; EDN, eosinophil-derived neurotoxin.